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Morphine and other agonists of the μ-opioid receptor are used clinically for acute and chronic pain relief and are considered
to be the gold standard for pain medication. However, these opioids also have significant side effects, which are also
mediated via activation of the μ-opioid receptor. Since the latter half of the twentieth century, researchers have sought to
tease apart the mechanisms underlying analgesia, tolerance and dependence, with the hope of designing drugs with fewer
side effects. These efforts have revolved around the design of orthosteric agonists with differing pharmacokinetic properties
and/or selectivity profiles for the different opioid receptor types. Recently, μ-opioid receptor-positive allosteric modulators
(μ-PAMs) were identified, which bind to a (allosteric) site on the μ-opioid receptor separate from the orthosteric site that
binds an endogenous agonist. These allosteric modulators have little or no detectable functional activity when bound to the
receptor in the absence of orthosteric agonist, but can potentiate the activity of bound orthosteric agonist, seen as an
increase in apparent potency and/or efficacy of the orthosteric agonist. In this review, we describe the potential advantages
that a μ-PAM approach might bring to the design of novel therapeutics for pain that may lack the side effects currently
associated with opioid therapy.
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C6-μ cells, C6 glioma cells expressing rat μ-opioid receptors; DAMGO, [D-Ala2, N-MePhe4, Gly-ol5]-enkephalin; μ-PAM,
μ-opioid receptor positive allosteric modulator; NAM, negative allosteric modulator; PAM, positive allosteric modulator;
SAM, silent allosteric modulator ; U2OS cells, human osteosarcoma cells
Introduction
Pain and opioid analgesics
Pain is the most common ailment for which people seek
medical attention. Chronic pain is a problem for millions of
patients and can be disabling, interfering with day-to-day
functions both at home and in the workplace. Costs in the
United States from healthcare expenditure and lost work time
due to pain are estimated at $100 billion/year (Melnikova,
2010).
Opioid receptors are key targets in the management of
pain (Przewlocki and Przewlocka, 2001; Vallejo et al., 2011).
Drug therapies derived from morphine, its derivatives and
other small molecules induce pain relief by acting as agonists
at opioid receptors, particularly the μ-opioid receptor
(Alexander et al., 2013). Morphine-induced analgesia is lost
in mice lacking the μ-opioid receptor gene (Matthes et al.,
1996). Opioid drugs can produce serious side effects, includ-
ing respiratory suppression, constipation, allodynia, toler-
ance, dependence and withdrawal symptoms, as well as
rewarding effects and abuse potential (Przewlocki and
Przewlocka, 2001; McNicol et al., 2003). All of these effects are
reversed by μ-opioid receptor antagonists and absent in
μ-opioid receptor-knockout animals (Matthes et al., 1996),
showing that they are mediated through activation of the
μ-opioid receptor.
Since the early 1990s, there has been a significant increase
in the use of opiate analgesics for non-cancer chronic pain,
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partly due to the belief that opiate dependence and addiction
liability had previously been overstated (Juurlink and Dhalla,
2012). However, this has led to a substantial increase in
patients with opiate dependence and addiction. The
increased presence of opiates in the household has also led to
higher abuse, both accidental and intentional, leading to
increased admissions to hospitals for treatment (Woodcock,
2009). Thus, physicians walk a tightrope balancing act in an
attempt to achieve both effective pain management and drug
safety.
The ‘holy grail’ of opioid research has been, and contin-
ues to be, the identification of drugs that can produce the
beneficial analgesic effects of opiates without the develop-
ment of tolerance or other side effects, including their clear
abuse liability. Over the past several decades, many opioid
ligands have been synthesized, with varying affinities for the
opioid receptor types, and varying pharmacokinetic proper-
ties. Combinations of these ligands have also been used
(Snyder and Pasternak, 2003; Corbett et al., 2006; Lambert,
2008). However, these efforts have not yet yielded dramatic
improvements in the availability of pain medications with
fewer side effects.
Opioid receptors
Opioid receptors are categorized within the Class A family of
GPCRs. Four opioid receptor types exist; μ-opioid receptors,
κ-opioid receptors, δ-opioid receptors and NOP receptors
(also known as ORL1) (Alexander et al., 2013; Cox et al.,
2015). These receptors were cloned in the 1990s (Evans
et al., 1992; Kieffer et al., 1992; Chen et al., 1993; Yasuda et al.,
1993; Mollereau et al., 1994; Raynor et al., 1994), and their
crystal structures have recently been elucidated (Granier
et al., 2012; Manglik et al., 2012; Thompson et al., 2012; Wu
et al., 2012). The opioid receptors share about 60% amino
acid identity (mainly within the transmembrane domains)
and signal through the Gi/o family of heterotrimeric G pro-
teins, resulting in inhibition of adenylate cyclase (AC), modu-
lation of ion channel activity (via G protein βγ subunits), and
transcriptional changes in the cell (Waldhoer et al., 2004).
There is also evidence for activation of non-G protein-
mediated pathways via β-arrestin (Bohn et al., 1999).
The endogenous ligands for the opioid receptors are pep-
tides derived from large precursors and include the enkepha-
lins, endorphins and dynorphins, which have selective
affinities for each of the three main opioid receptor types
(Janecka et al., 2004) but very low affinity for the NOP recep-
tor. The endomorphins (Zadina et al., 1997) are considered
putative endogenous μ-opioid receptor ligands. The endog-
enous peptide for the NOP receptor is nociceptin/orphanin
FQ peptide (Meunier et al., 1995; Reinscheid et al., 1995),
which has no affinity for μ-, κ- or δ-opioid receptors.
Opiate physical dependence correlates closely with the
development of opiate tolerance (Way et al., 1969), suggest-
ing that they may share common mechanisms. Tolerance can
be defined as a reduced response to repeated administration
of the same dose of drug, or put another way, increased doses
of drug are required to produce the same magnitude of
response. There have been considerable studies investigating
the underlying mechanisms that result in opioid tolerance
and dependence, which have been reviewed elsewhere
(Bailey and Connor, 2005; Sadee et al., 2005; Bian et al., 2012;
Whistler, 2012; Williams et al., 2013). Hypotheses include
μ-opioid receptor phosphorylation and desensitization,
receptor internalization/down-regulation, and up-regulation
of AC. It has been suggested that the intracellular β-arrestin-2
protein is significantly involved in agonist-mediated devel-
opment of tolerance, based on the fact that β-arrestin-2
knockout mice have enhanced analgesic effects in response to
morphine and lower levels of receptor desensitization, and
other unwanted side effects (Bohn et al., 1999). However,
despite several decades of research, the mechanistic under-
standing of how tolerance develops is still relatively poorly
understood.
Orthosteric and allosteric ligands
Before we introduce the concept of allosteric modulators, it is
beneficial to start with orthosteric ligand interactions with
GPCRs. Orthosteric ligands bind to the same site on the
receptor that recognizes an endogenous agonist – in the case
of the opioid receptors these are the opioid peptides. GPCRs
exist in multiple conformational states, but for simplicity we
will only refer to two, an inactive (R) conformation and an
active (R*) conformation. Orthosteric agonists bind with
higher affinity to R*, thus driving the receptor equilibrium
from R towards R* to give a high R*/R ratio. Based on the
intrinsic activity of a given agonist, the agonist can be full
(eliciting a maximal achievable response in that system) or
partial (where the elicited response is less than that of a full
agonist despite full occupancy of all the available receptor
binding sites). This can be explained by a reduced ability of
partial agonists to differentiate R and R*, thereby producing a
lesser equilibrium shift towards R* than full agonists and/or
an ability to induce a different active conformation of the
receptor (R+), which produces less activation of effectors (e.g.
G proteins) compared with R* (Tota and Schimerlik, 1990).
The phenomenon of biased agonism (Kenakin, 2011) con-
firms the existence of multiple active conformations of the
receptor, but the simple R and R* model is clearly useful
because it leads to predictions that are supported by experi-
mental evidence. For example, high-efficacy agonists show a
greater binding affinity shift (from high affinity to low affin-
ity) in the presence of guanine nucleotides, compared with
lower efficacy agonists (Evans et al., 1985; Emmerson et al.,
1996).
The demonstration of constitutive GPCR activity (Costa
and Herz, 1989) indicated that receptors could form the R*
state and activate G proteins even in the absence of ligand.
Ligands termed ‘inverse agonists’ bind with higher affinity to
the R conformation of the receptor, thus driving the receptor
equilibrium from R* towards R and inhibiting constitutive
activity of the receptor. Neutral antagonists show no pre-
ference for binding to the R or R* state and therefore do
not affect the equilibrium of receptor conformations, but
compete with orthosteric agonists for the orthosteric binding
site. The ability to detect constitutive activity in recombinant
systems expressing high levels of receptors suggests that most
compounds thought to be neutral antagonists may show
some preference for R or R*, and are either very weak efficacy
agonists or weak efficacy inverse agonists.
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It has become increasingly evident that certain ligands
can bind to sites on GPCRs that are separate (allosteric) from
the orthosteric site. The term ‘allosteric’ from the Greek
‘other site’ was first coined in a journal title 50 years ago by
Monod, Changeux and Jacob (Monod et al., 1963), followed 2
years later by the Monod, Wyman and Changeux model
(Monod et al., 1965) which describes a two-state model where
proteins can exist spontaneously in two conformations, an
active and inactive state. Orthosteric and allosteric ligands
binding to their respective (non-overlapping) binding sites
can stabilize one receptor state at the expense of the other.
The effects observed from interactions between the orthos-
teric and allosteric ligands, binding to the protein, were
termed the ‘allosteric interactions’.
The concept of allostery was first applied to GPCRs with
the development of the ternary complex model (De Lean
et al., 1980), which described the interactions between
agonist, receptor and G protein, where the G protein can be
considered as the allosteric modulator, binding at the intra-
cellular side of the receptor. At around the same time, an
introduction to the allosteric ternary complex model for
GPCRs was also described based on the observed effects of
gallamine on muscarinic receptors, which led to the conclu-
sion that gallamine binds to a site distinct from other mus-
carinic agonists and antagonists (Clark and Mitchelson, 1976;
Stockton et al., 1983). Further modifications to these models
to account for receptor constitutive activity led to the
extended ternary complex model (Samama et al., 1993) and
the more thermodynamically complete cubic ternary
complex model (Weiss et al., 1996), which applies specifically
to two states of the receptor and their interactions with G
proteins. The allosteric two-state model (Hall, 2000) looks
very similar to the cubic ternary complex model but substi-
tutes G protein (G) with allosteric ligand (B), and applies
more directly to orthosteric and allosteric ligands interacting
with active and inactive conformations of the receptor. For a
comprehensive review, see Christopoulos and Kenakin, 2002.
From a drug discovery perspective, the aim is to first
identify and then to monitor the structure activity relation-
ship of allosteric compounds using functional assays. An
operational model has been developed based on the allosteric
binding models of Ehlert (Ehlert, 1988) and the Black & Leff
operational model of agonism (Black and Leff, 1983) that
tracks the allosteric cooperativity factors (αβ). The final deri-
vation of this operational model is shown in Scheme 1 as
presented by Leach and colleagues (Leach et al., 2007).
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Within this model, E is the pharmacological effect, KA and KB
denote the equilibrium binding constants for the orthosteric
ligand, A, and the allosteric ligand, B, at the receptor. The
binding cooperativity factor, α, represents the effect of the
allosteric ligand on orthosteric agonist binding affinity, and
vice versa. An activation cooperativity factor, β, denotes the
effect the allosteric ligand has on orthosteric agonist efficacy.
Agonism constants τA and τB represent the intrinsic activity of
the orthosteric agonist and any intrinsic activity of the allos-
teric ligand, respectively, which is dependent on the cell
context and receptor expression level of the cell system, and
intrinsic efficacy of the ligands used. The remaining param-
eters, Em and n, denote the maximal response of the system,
and the slope, respectively. A simplified cartoon representing
components of the operational model and how they apply to
the various modes of allosteric modulation observed is shown
in Figure 1.
These parameters lead to the multiple ‘flavours’ of allos-
teric ligands that can be observed. Allosteric agonists that can
activate the receptor even in the absence of an orthosteric
agonist, have τB activity, leading to functional efficacy that
appears similar to an orthosteric agonist. Allosteric inverse
agonists bind to an allosteric site and inhibit the constitutive
activity of the receptor in the absence of orthosteric ligand.
However, allosteric modulators may have very weak or unde-
tectable intrinsic efficacy when they bind to the receptor, but
can positively or negatively modulate (via α and/or β) the
binding affinity and/or efficacy of the orthosteric agonist
when it binds to the receptor. Compounds with combined
cooperativity factor (αβ) values > 1 are considered positive
allosteric modulators (PAMs) and result in increased apparent
potency and/or efficacy of the orthosteric agonist response.
This is typically manifest as leftward shifts in the
concentration-response curve for the orthosteric agonist in
the presence of the PAM. Systems with spare receptors ‘recep-
tor reserve’ exhibit leftward shifts in the orthosteric agonist
concentration-response curve with increases in α or β. In
these cases, one cannot discern the contribution of α or β
from the functional assay, but only the combined coopera-
tivity effect (αβ). The magnitude of these leftward shifts
increases with increasing PAM concentration, until the PAM
effect saturates when the allosteric sites are fully occupied.
Therefore, beyond this concentration of PAM there is no
further leftward shift in the agonist concentration-response
curve. The maximal ‘fold-shift’ in agonist potency is equal to
the cooperativity factor (αβ), and the concentration of PAM
which induces a half-maximal leftward fold-shift of the
orthosteric agonist potency is termed the apparent KB
Figure 1
Modes of allosteric modulation. Allosteric ligands (B) bind to a topo-
graphically distinct site on the receptor compared with the orthos-
teric agonist (A), and can modulate orthosteric agonist binding
affinity (α), orthosteric agonist efficacy (β), and may have intrinsic
agonist activity (τB). Cartoon is a modified figure from Conn et al.,
2009a.
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(equilibrium binding constant for the PAM), or more collo-
quially the ‘shifty50’ (Hendricson et al., 2012). It is fairly
common for allosteric ligands to have a combination of both
allosteric agonist (τB) and PAM (αβ) activities depending on
the cellular system, and the assay used to monitor functional
activity. In these cases, direct agonism is typically seen at
significantly higher concentrations of the allosteric ligand
than are required for PAM activity (Burford et al., 2011).
Negative allosteric modulators (NAMs) have combined αβ
values <1, resulting in a reduction in the potency and/or
efficacy of the orthosteric agonist response. Compounds that
bind to the allosteric site with very weak or no PAM or NAM
activity are essentially neutral allosteric ligands or silent allos-
teric modulators (SAMs). These SAMs act as competitive
antagonists at the allosteric site, and are therefore useful for
characterizing the site of action of identified PAMs and
NAMs.
The classification of ligands as agonists, partial agonists,
neutral antagonists, inverse agonists, allosteric agonists,
PAMs, NAMs and SAMs is dependent on the cellular system
evaluated, and the particular aspect of signalling being
explored. Also, for allosteric ligands, the allosteric coopera-
tivity can be different depending on which particular orthos-
teric agonist (probe) is used (Jager et al., 2007; Koole et al.,
2010). This is referred to as probe dependence. Therefore,
defining a specific compound as a PAM or a NAM should only
be done in the context of the cellular system, the agonist
probe and the assay used.
Moreover, the situation is even more complex. For
example, with homo- and hetero-oligomers (Gomes et al.,
2004; Gupta et al., 2010; Costantino et al., 2012; Stockton
and Devi, 2012) the partnering receptor can be considered
the allosteric modulator (Gomes et al., 2004) causing confor-
mational changes in the target receptor that may affect
orthosteric agonist affinity and/or efficacy, as well as possible
signalling bias. It is reasonable to assume both orthosteric
and allosteric ligands that bind to one receptor in the
complex will alter this allosteric interaction between GPCRs.
Allosteric ligands have several potential advantages over
traditional orthosteric ligands as drugs (Christopoulos and
Kenakin, 2002; Leach et al., 2007; May et al., 2007; Conn
et al., 2009a; Burford et al., 2011; Keov et al., 2011;
Langmead, 2012). Because they do not bind to highly con-
served orthosteric binding pockets, allosteric ligands can
exhibit greater receptor selectivity. Additionally, PAMs have
key potential advantages over orthosteric agonist drugs:
PAMs can increase the amplitude while maintaining the
spatial and temporal fidelity, and the physiological regula-
tion, of native signalling patterns – something that orthos-
teric agonist drugs cannot come close to doing. These key
features of PAMs are illustrated in Figures 2 and 3, and dis-
cussed below.
Discovery of μ-opioid receptor positive
allosteric modulators (μ-PAMs)
Recently our group discovered μ-PAMs, which to our knowl-
edge are the first PAMs described in the literature for this
receptor (Burford et al., 2013). Two negative allosteric modu-
lators of opioid receptors have been described previously.
Cannabidiol (a cannabinoid CB1 receptor agonist) has been
shown to be a negative allosteric modulator of agonist
binding to μ- and δ-opioid receptors (Kathmann et al., 2006).
Salvinorin-A is a potent hallucinogenic κ-opioid receptor
Figure 2
PAMs maintain spatial fidelity of native signalling. Endogenous opioid agonist is released at locations in the brain or spinal cord where it is required,
maintaining the spatial fidelity of native signalling (A). Exogenous agonist is distributed and can activate target receptors throughout the body.
This may lead to ‘on target’ side effects (B). PAMs can enhance the effects of endogenous agonists while still maintaining the spatial fidelity of
native signalling (C).
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agonist (Sheffler and Roth, 2003), but has also been shown to
be a negative allosteric modulator of the μ-opioid receptor,
although with ∼100-fold weaker potency than its activity at
κ-opioid receptor (Rothman et al., 2007). μ-PAMs were iden-
tified in a high-throughput screen using a β-arrestin recruit-
ment assay (PathHunter technology, DiscoveRx Corp.,
Fremont, CA, USA) (Bassoni et al., 2012) in human osteosar-
coma cells (U2OS) cells expressing μ-opioid receptors. In this
assay, compounds were tested alone (agonist detection mode)
or in the presence of a low (approximately EC10) concentra-
tion of the μ-opioid receptor agonist, endomorphin-I (PAM
detection mode). Concentration–response curves of the
screening hits were evaluated in U2OS cells expressing
μ-opioid receptors (U2OS-OPRM1 cells) and in U2OS cells
expressing δ-opioid receptors (U2OS-OPRD1 cells) in the
β-arrestin assay, in both agonist and PAM detection modes.
Two of the compounds identified (BMS-986121 and BMS-
986122) showed no agonist activity, were selective for μ- over
δ-opioid receptors, and produced a sevenfold leftward shift
(αβ = 7) in the potency of endomorphin-I in the β-arrestin
assay in U2OS-OPRM1 cells.
These PAMs were further evaluated in an inhibition of
forskolin-stimulated cAMP assay in CHO cells expressing
μ-opioid receptors. In this assay, the PAMs produced leftward
shifts in the potency of endomorphin-I as well as two other
μ-opioid receptor agonists, leu-enkephalin and morphine.
Interestingly, both PAMs showed some direct agonist activity
in this assay format (τB in Figure 1), although at much weaker
potencies than were observed for PAM activity.
Further confirmation that these compounds were μ-PAMs
came from ligand binding studies and studies with a radiola-
belled, poorly hydrolysed analogue of GTP ([35S]-GTPγS) using
membranes from C6 glioma cells expressing rat μ-opioid
receptors (C6-μ cells) and mouse brain homogenates. Binding
studies in C6-μ cell membranes showed that while the affinity
of radiolabelled antagonist [3H]-diprenorphine was unaf-
fected by the μ-PAMs, competition of [3H]-diprenorphine
binding with the selective full agonist [D-Ala2, N-MePhe4,
Gly-ol5]-enkephalin (DAMGO) showed that the μ-PAMs
increased the affinity of DAMGO by sixfold, suggesting that
these μ-PAMs act, at least in part, by increasing the affinity of
the orthosteric agonist binding to the receptor (α in Figure 1).
However, in [35S]-GTPγS binding studies, under conditions
where morphine and endomorphin-I were shown to be
partial agonists compared with DAMGO, the μ-PAMs were
shown to enhance the maximal response of these partial
agonists, suggesting that they also can positively modulate
the efficacy of responses to agonists (β in Figure 1).
Compounds similar in structure to BMS-986122 were
tested in the β-arrestin recruitment assay resulting in some
interesting structure activity relationships. Small changes in
structure resulted in greatly reduced μ-PAM activity, although
the EC50 of the responses were similar. It was subsequently
shown that some of these compounds were SAMs, binding to
the allosteric site but having no detectable effect in modulat-
ing the activity of the orthosteric agonist. However, the SAMs
could block the activity of the μ-PAM, BMS-986122. Some of
the BMS-986122 analogues also showed some δ-opioid recep-
tor PAM activity, suggesting that μ- and δ-opioid receptors
may share a similar allosteric site, and that selectivity
between μ- and δ-opioid receptors can be engineered into the
compounds.
Figure 3
PAMs maintain temporal fidelity of native signalling. Endogenous agonist can be released and cleared or metabolized quickly, leading to signalling
effects that have temporal fidelity (A). Exogenous agonist occupies receptors constantly, leading to effects that last until the drug is cleared or
metabolized (B). PAMs can enhance the effects of endogenous agonists while still maintaining the temporal fidelity of native signalling (C).
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Key features of PAMs compared with
orthosteric agonists
Receptor selectivity
Receptors binding the same native agonist(s) necessarily
exhibit high homology at the orthosteric agonist binding
site. Thus, the identification of orthosteric ligands with selec-
tivity between these related receptors can be difficult. This
has posed major challenges for drug discovery programmes,
where often one particular receptor type or subtype is the
desired therapeutic target, but activity at related receptors can
lead to undesired side effects. Well-known examples include
the metabotropic glutamate receptors, muscarinic receptors
and adenosine receptors, for which selective orthosteric
ligands have remained elusive throughout decades of
research. In contrast, allosteric sites on GPCRs do not bind
the native ligand, and therefore are not under the same
evolutionary constraint as orthosteric sites. Presumably
because of an increased diversity at allosteric binding pockets,
it has been possible to identify several highly selective allos-
teric agonists and PAMs for the notoriously difficult receptor
targets listed above (Bruns and Fergus, 1990; Gasparini et al.,
2002; Birdsall and Lazareno, 2005; Gao et al., 2005; Conn
et al., 2009b).
For opioid receptors, orthosteric agonist selectivity
between the receptor types has largely been achieved through
decades of medicinal chemistry programmes. However, allos-
teric agonists and PAMs may offer new structural scaffolds to
further improve receptor type selectivity.
Because of the lack of evolutionary constraint imposed
upon allosteric sites, allosteric ligands may be species-
selective as well as receptor-selective. This can pose serious
issues for drug development where a compound active at
receptors in mice or rats may have no activity at the human
orthologue, or vice versa. Therefore, activity of allosteric
ligands at receptor orthologues should be determined early in
the drug discovery programme. For the μ-PAMs discovered by
our group, we saw no species selectivity between human, rat
or mouse orthologues of the μ-opioid receptor.
Maintenance of temporal and spatial fidelity
Another advantage of PAMs is that they can maintain the
temporal and spatial activity of receptor signalling in vivo.
This is illustrated in Figures 2 and 3.
Neuronal signals are closely regulated within the nervous
system with a high degree of temporal and spatial precision.
When an orthosteric agonist drug is added systemically, it has
two major disadvantages. Firstly, it is available throughout
the body and not just at the specific location where it is
needed. This leads to activation of target receptors in other
areas of the brain and in other tissues, which can be detri-
mental to the therapeutic potential of the drug (Figure 2).
Secondly, the added drug activates all the receptors through-
out the body for an extended period of time. Usually, neuro-
transmitter release is pulsatile in nature and quickly removed
between bursts of activity. Continuous exposure to an orthos-
teric agonist drug for extended periods of time may lead to
receptor desensitization and tachyphylaxis, as well as toxic
side effects mediated by long-term exposure of drug at the
receptor (Figure 3).
These disadvantages of orthosteric drugs may be over-
come with PAM drugs, where activity of an endogenously
released orthosteric agonist are enhanced by the PAM, with
the PAM having no effect at the receptor when the receptor is
not bound with endogenous agonist. Such drugs would
maintain the native temporal and spatial activity of the
receptor in response to endogenous agonist.
Based on the pharmacological principle above, one can
clearly envisage one potential way that μ-PAMs could provide
an advantage over current orthosteric opiate analgesic
therapy: μ-PAMs could produce analgesia by enhancing the
activity of the endogenous opioid peptide ligands in pain-
mediating pathways of the central and peripheral nervous
system. In this way, the temporal and spatial activity of the
endogenous opioid peptides would be preserved, and side
effects resulting from continuous and indiscriminate activa-
tion of opioid receptors may be averted. This hypothesis
raises several key questions: Does significant endogenous
opioid signalling occur physiologically (i.e. is there enough
endogenous opioid signals to amplify)? Does this endog-
enous signalling increase under conditions of injury, or
chronic inflammatory or neuropathic pain? Are such
increases spatially and/or temporally specific? Evidence for an
endogenous peptide agonist-induced tone for μ-opioid recep-
tor activity does exist. For example, inhibition of enkephali-
nases, which break down endogenous opioid peptides, results
in antinociception in animal models of inflammatory and
neuropathic pain (Roques et al., 2012). Similarly, naloxone, a
μ-opioid receptor antagonist, increased pain perception when
administered to post-operative patients who were not taking
exogenous opiates, suggesting the endogenous opioid pep-
tides produced a basal analgesic tone (Levine et al., 1978).
Recently, opioid receptor antagonists were also shown to
increase hyperalgesia in acute and chronic inflammatory pain
models in mice that had not been treated with exogenous
opioids (Corder et al., 2013). The authors suggested that
initial release of endogenous opioids leads to constitutive
activation of the μ-opioid receptor, resulting in long-term
endogenous analgesia.
The development of μ-PAMs will allow researchers to test
whether, when administered alone, they will have efficacy in
pain relief models, and whether the side effect profiles may be
better compared with current opiate therapy. Of particular
interest is whether tolerance and dependence can be avoided
with a μ-PAM therapeutic. As the receptors would not be
activated all the time by an exogenous agonist, one can
hypothesize there will be less tolerance and dependence
liability.
A second potential therapeutic utility for μ-PAMs can be
envisaged: It is possible that administration of a low dose of
opiate with a μ-PAM may also provide therapeutic benefit but
with fewer side effects. The combination of a lower dose of
opiate enhanced by a μ-PAM might slow or reduce the devel-
opment of tolerance, which results from long-term exposure
to opiates. There is precedence for this behaviour at the
GABAB receptor. The potency of GABA to inhibit forskolin-
induced cAMP formation in recombinant cells decreased after
exposure to a saturating GABA concentration, but not after a
combination of a low GABA concentration and the PAM
GS39783, which activated the receptor to the same extent
(Gjoni and Urwyler, 2008). The authors suggested that
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GS39783 has a lower propensity to develop tolerance due to
less receptor desensitization than classical agonists. It will be
interesting to see whether a low dose of morphine combined
with μ-PAM can produce similar levels of pain relief as a high
dose of morphine, but with fewer tolerance and dependence
liabilities.
Most of the untoward side effects of opiates (e.g. respira-
tory depression, constipation) are mediated through μ-opioid
receptors, and there is no a priori reason to assume that
μ-PAMs would not potentiate these unwanted effects of
opiates as well as their desired therapeutic effects. However,
perhaps the on-target side effects might be minimized by
using reduced concentrations of morphine.
Finite shifts in orthosteric agonist potency
with increasing concentrations of PAM
Modulation of orthosteric agonist responses by PAMs or
NAMs is finite. As modulator concentrations reach the point
where the allosteric binding sites on all available receptors are
occupied, then no additional change in orthosteric agonist
functional potency or efficacy is observed, even when the
concentration of PAM or NAM is increased further. Therefore,
allosteric modulators can be designed and selected based on
their ability to produce a defined ‘fold-shift’ in functional
potency of the orthosteric agonist. The main advantage of
this is that PAMs with a defined fold-shift of agonist potency
may reduce toxicity or avoid overdosing of the patient.
This would clearly be a potential benefit for the use of
μ-PAMs where overdose with opiate drugs is a serious issue,
resulting in many deaths. In many of these cases, the need to
take more drug to overcome receptor tolerance issues com-
pounds the problem.
Probe dependence
Another important aspect of allostery is the fact that the level
or appearance of allosteric modulation can depend upon the
orthosteric agonist ligand used, as described above. This has
important consequences. Firstly, when evaluating com-
pounds as PAMs, one should use, whenever possible, the
endogenous ligand. This can add a level of complexity to a
drug discovery programme when multiple endogenous
ligands exist. Additionally, it is of note that previously inac-
tive or weak potency metabolites of the endogenous ligand
may show significant activity in the presence of a PAM.
Therefore, probe dependence is an important consideration
when evaluating the therapeutic potential of a given PAM
(Wootten et al., 2012).
Opioid receptors have multiple endogenous peptide
agonist ligands. So it will be important to establish how each
of these ligands is modulated by PAMs. Firstly, the selectivity
of the PAM for each of the opioid receptors should be deter-
mined. If a PAM is found to be μ-opioid receptor-selective,
one must also consider whether peptide agonists that are
more κ-opioid receptor-selective but with some μ-opioid
receptor activity (e.g. dynorphin-A) become more active at
the μ-opioid receptor, and what consequences that has on the
various pathways controlled by endogenous peptides. Simi-
larly, metabolites of these peptides, which may not have
much affinity/efficacy for opioid receptors, may produce sig-
nificant activity in the presence of an opioid receptor PAM.
Metabolism of morphine and other opiates also produce
metabolites which are inactive at the μ-opioid receptor.
However, one must ensure that these metabolites in the
presence of a μ-PAM do not produce significant activity at
the receptor, and if they do, one must determine the
consequences.
Ligand-biased signalling and
biased modulation
Historically, receptor pharmacology has been thought of in
relatively simplistic terms, where ligands bind to and activate
a receptor leading to a defined cascade of signalling pathways
within the cell. However, over the past decade, research has
convincingly shown that ligands acting at the same receptor
can activate different signalling pathways, with each ligand
producing subtly different changes in conformations of the
receptor when they are bound. This feature, commonly called
signalling bias or functional selectivity, has greatly increased
our understanding of receptor pharmacology and revolution-
ized approaches to drug discovery (Kenakin, 2011; Whalen
et al., 2011; Kenakin and Christopoulos, 2013). The possibil-
ity of identifying small molecule orthosteric agonist ligands
that can preferentially activate certain signalling pathways
and not others offers the potential to discriminate between
therapeutically beneficial pathways and unwanted side effect
pathways even when the side effects are mediated by the
target receptor, as is the case for the μ-opioid receptor.
Recently, there has been a great deal of interest in signal-
ling bias with various opioid receptor ligands, and ligand bias
has been observed with respect to agonist-mediated phospho-
rylation and internalization of the μ-opioid receptor, inhibi-
tion of cAMP accumulation, ion channel activity, β-arrestin
recruitment responses and other non-canonical signalling
pathways (Burford et al., 1998; Mailman, 2007; Violin and
Lefkowitz, 2007; Rivero et al., 2010; McPherson et al., 2012;
Pradhan et al., 2012; Rives et al., 2012). Based on observations
from β-arrestin-2 knockout mice that β-arrestins serve as
negative modulators of analgesia, and positive modulators of
some μ-opioid receptor-related side effects (including toler-
ance) (Bohn et al., 1999; 2000), it has been hypothesized that
opioid agonists with bias toward the G protein-mediated
pathways and away from the β-arrestin-mediated pathways
may be beneficial in separating the analgesic effects from the
side effects. Indeed, Trevena have recently identified a G
protein-biased agonist of the μ-opioid receptor, TRV130,
which is reported to be a potent analgesic but with reduced
gastrointestinal and respiratory dysfunctional effects com-
pared with morphine (Dewire et al., 2013).
Very recently, phosphorylation of the μ-opioid receptor at
Tyr336 by Src has been shown to serve as the trigger for con-
version of a classical Gi/Go-coupled receptor into a receptor
tyrosine kinase-like entity, resulting in a non-canonical
pathway leading to increased activation of AC even after the
original Gi/Go signals are blunted (Zhang et al., 2013).
Above, we have described the potential advantages of
ligand bias signalling with respect to orthosteric agonists at
the μ-opioid receptor. However, it is conceivable that a PAM
may change the active conformation of the receptor in the
presence of agonist, thus changing the signalling cascade to
be biased towards one pathway and away from another. This
‘biased modulation’ has been observed for many GPCRs and
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these have been recently reviewed elsewhere (Koole et al.,
2010; Keov et al., 2011; Davey et al., 2012; Kenakin and
Christopoulos, 2013; Wootten et al., 2013).
Conclusions
The discovery and characterization of μ-PAMs has opened up
a new and exciting avenue to explore not only novel pain
therapeutics at the μ-opioid receptor, but also therapeutics for
conditions, such as mood disorders, for which there is
mounting evidence that opioid receptors present viable
therapeutic targets (Lambert, 2008; Hegadoren et al., 2009;
Lutz and Kieffer, 2013). With the design of improved μ-PAMs
with higher affinity for the receptor and better pharmacoki-
netic, pharmacodynamic, and safety profiles, it will be possi-
ble to assess whether μ-PAMs have efficacy in models of pain
relief and other medical conditions either when administered
alone, thereby modulating endogenous opioid pathways, or
in combination with lower concentrations of exogenous
opiates, such as morphine. In either scenario, it will be impor-
tant to know if beneficial actions are enhanced, while sparing
tolerance, dependence and other side effects associated with
current opioid therapies.
Nevertheless, there are also a number of challenges for
any drug discovery programme seeking allosteric modulators
of opioid receptors. Due to the probe-dependent nature of
allosteric modulation and the non-selectivity of several of
the endogenous opioid peptides and opioid drugs, the activ-
ity of opioid PAMs will need to be assessed across opioid
receptor types and with a variety of endogenous and other
orthosteric agonists, including potentially active metabolites
(Wootten et al., 2012). An additional complication is that
some chemical scaffolds, including the μ-PAMs we have
described (Burford et al., 2013) can switch function from
PAMs to NAMs or SAMs with only small changes in structure
(Melancon et al., 2012). However, there is no doubt that the
inherent advantages of PAMs, especially their maintenance
of temporal and spatial signalling fidelity and promise of
biased modulation, in addition to the potential to use lower
doses of opioid drugs, will guide research over the next few
years. This will ascertain whether μ-PAMs might represent
the ‘holy grail’ of opioid research, developing powerful
analgesic drugs devoid of the side effects associated with
morphine.
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